

### **REMARKS**

The specification is amended. The issue replacement material is a copy of text from an issued patent. De fact, it should be acceptable.

Cancellation of SEQ ID NOS: 13-15 from the claims eliminates the Terminal Disclaimer issue.

Claims 19-21, 23, and new claim 24 are presented. Claim 19 is amended to incorporate claim 22 therein, with the exception of SEQ ID NO: 6. This is believed to address the prior art rejection.

New claim 24 is directed to SEQ ID NO: 9, which is indicated by the Examiner to be free of prior art.

Regarding claim 19, amendments have been presented to address the Examiner's concerns. In brief, the polytope must contain one of the recited sequences, but could contain more peptides. When processed intracellularly, the recited peptide forms a complex with an HLA molecule. In turn, the complex provokes a CTL response.


All issues are believed addressed. Withdrawal of the rejections is urged.

\* \* \*

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. NY-LUD 5483-US7-DIV (10316191) from which the undersigned is authorized to draw.

Dated: 10/29/07

Respectfully submitted,

By 

Norman D. Hanson  
Registration No.: 30,946  
FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000  
(212) 318-3400 (Fax)  
Attorney for Applicant

Application No. 10/758,673  
Amendment dated October 29, 2007  
After Final Office Action of August 9, 2007

Docket No.: NY-LUD 5483-US7-DIV

**REPLACEMENT SHEETS**

